Bausch + Lomb (BLCO) announced CE Mark approval for the LuxLife full range of vision intraocular lens. The preloaded IOL provides patients with natural, continuous vision, from distance to near.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch Health price target lowered to $8 from $9 at Raymond James
- Bausch + Lomb price target lowered to $15 from $20 at H.C. Wainwright
- Bausch + Lomb price target lowered to $12 from $15 at Wells Fargo
- Bausch + Lomb price target lowered to $11 from $17 at BofA
- Bausch + Lomb price target lowered to $13 from $14 at Citi